Egyptian International Pharmaceutical Industries Company, commonly known as EIPICO, is a leading player in the pharmaceutical industry, headquartered in Egypt. Established in 1980, EIPICO has made significant strides in the production of high-quality generic medications, catering to both local and international markets. With a strong operational presence across the Middle East and North Africa, EIPICO focuses on a diverse range of therapeutic areas, including antibiotics, cardiovascular drugs, and anti-diabetics. The company is renowned for its commitment to innovation and quality, utilising advanced manufacturing techniques to ensure the efficacy and safety of its products. EIPICO's dedication to excellence has positioned it as a market leader, achieving notable milestones in production capacity and regulatory compliance. With a robust portfolio of over 200 products, EIPICO continues to contribute significantly to the healthcare landscape in Egypt and beyond.
How does Egyptian International Pharmaceutical Industries Company's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Egyptian International Pharmaceutical Industries Company's score of 22 is lower than 83% of the industry. This can give you a sense of how well the company is doing compared to its peers.
The Egyptian International Pharmaceutical Industries Company (EIPICO), headquartered in Egypt, currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Additionally, there are no documented reduction targets or climate pledges associated with the company. As a result, EIPICO's climate commitments and initiatives remain unclear, and there is no information available regarding their strategies for addressing carbon emissions or contributing to sustainability efforts within the pharmaceutical industry. The lack of emissions data and reduction initiatives suggests that EIPICO may need to enhance its focus on climate action and transparency in environmental reporting.
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Egyptian International Pharmaceutical Industries Company is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.